Literature DB >> 31413802

Novel Small Molecule-Derived, Highly Selective Substrates for Fibroblast Activation Protein (FAP).

An De Decker1, Gwendolyn Vliegen2, Dries Van Rompaey1, Anke Peeraer1, An Bracke2, Line Verckist3, Koen Jansen1, Ruth Geiss-Friedlander4, Koen Augustyns1, Hans De Winter1, Ingrid De Meester2, Anne-Marie Lambeir2, Pieter Van der Veken1.   

Abstract

Fibroblast activation protein (FAP) is a proline-selective serine protease. It is hardly expressed in healthy adult tissue but upregulated in tissue remodeling sites associated with several diseases including epithelial cancer types, atherosclerosis, arthritis and fibrosis. Ongoing research aims at clinical implementation of FAP as a biomarker for these diseases. Several immunochemical methods that quantify FAP expression have been reported. An alternative/complementary approach focuses on quantification of FAP's enzymatic activity. Developing an activity-based assay for FAP has nonetheless proven challenging because of selectivity issues with respect to prolyl oligopeptidase (PREP). Here, we present substrate-type FAP probes that are structurally derived from a FAP-inhibitor (UAMC1110) that we published earlier. Both cleavage efficiency and FAP-selectivity of the best compounds in the series equal or surpass the most advanced peptide-based FAP substrates reported to date. Finally, proof-of-concept is provided that 4-aminonaphthol containing probes can spatially localize FAP activity in biological samples.

Entities:  

Year:  2019        PMID: 31413802      PMCID: PMC6691567          DOI: 10.1021/acsmedchemlett.9b00191

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  28 in total

1.  Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts.

Authors:  J E Park; M C Lenter; R N Zimmermann; P Garin-Chesa; L J Old; W J Rettig
Journal:  J Biol Chem       Date:  1999-12-17       Impact factor: 5.157

2.  Selective inhibition of fibroblast activation protein protease based on dipeptide substrate specificity.

Authors:  Conrad Yap Edosada; Clifford Quan; Christian Wiesmann; Thuy Tran; Dan Sutherlin; Mark Reynolds; J Michael Elliott; Helga Raab; Wayne Fairbrother; Beni B Wolf
Journal:  J Biol Chem       Date:  2006-01-12       Impact factor: 5.157

3.  P2-substituted N-acylprolylpyrrolidine inhibitors of prolyl oligopeptidase: biochemical evaluation, binding mode determination, and assessment in a cellular model of synucleinopathy.

Authors:  Pieter Van der Veken; Vilmos Fülöp; Dean Rea; Melanie Gerard; Roos Van Elzen; Jurgen Joossens; Jonathan D Cheng; Veerle Baekelandt; Ingrid De Meester; Anne-Marie Lambeir; Koen Augustyns
Journal:  J Med Chem       Date:  2012-11-13       Impact factor: 7.446

4.  Activatable near-infrared fluorescent probe for in vivo imaging of fibroblast activation protein-alpha.

Authors:  Jinbo Li; Kai Chen; Hongguang Liu; Kai Cheng; Meng Yang; Jiping Zhang; Jonathan D Cheng; Yan Zhang; Zhen Cheng
Journal:  Bioconjug Chem       Date:  2012-07-31       Impact factor: 4.774

5.  In situ prolyl oligopeptidase activity assay in neural cell cultures.

Authors:  Linda Klimaviciusa; Rajeev Kumar Jain; Külli Jaako; Roos Van Elzen; Melanie Gerard; Pieter van Der Veken; Anne-Marie Lambeir; Alexander Zharkovsky
Journal:  J Neurosci Methods       Date:  2011-11-11       Impact factor: 2.390

6.  Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth.

Authors:  Jonathan D Cheng; Matthildi Valianou; Adrian A Canutescu; Eileen K Jaffe; Hyung-Ok Lee; Hao Wang; Jack H Lai; William W Bachovchin; Louis M Weiner
Journal:  Mol Cancer Ther       Date:  2005-03       Impact factor: 6.261

7.  Peptide substrate profiling defines fibroblast activation protein as an endopeptidase of strict Gly(2)-Pro(1)-cleaving specificity.

Authors:  Conrad Yap Edosada; Clifford Quan; Thuy Tran; Victoria Pham; Christian Wiesmann; Wayne Fairbrother; Beni B Wolf
Journal:  FEBS Lett       Date:  2006-02-03       Impact factor: 4.124

8.  Regulation of expression and function of dipeptidyl peptidase 4 (DP4), DP8/9, and DP10 in allergic responses of the lung in rats.

Authors:  Jutta Schade; Michael Stephan; Andreas Schmiedl; Leona Wagner; André J Niestroj; Hans-Ulrich Demuth; Nadine Frerker; Christian Klemann; Kerstin A Raber; Reinhard Pabst; Stephan von Hörsten
Journal:  J Histochem Cytochem       Date:  2007-10-29       Impact factor: 2.479

9.  FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells.

Authors:  Hyung-Ok Lee; Stefanie R Mullins; Janusz Franco-Barraza; Matthildi Valianou; Edna Cukierman; Jonathan D Cheng
Journal:  BMC Cancer       Date:  2011-06-13       Impact factor: 4.430

10.  Fibroblast activation protein is induced by inflammation and degrades type I collagen in thin-cap fibroatheromata.

Authors:  Chad E Brokopp; Roman Schoenauer; Peter Richards; Stefan Bauer; Christine Lohmann; Maximilian Y Emmert; Benedikt Weber; Stephan Winnik; Elena Aikawa; Kirk Graves; Michele Genoni; Peter Vogt; Thomas F Lüscher; Christoph Renner; Simon P Hoerstrup; Christian M Matter
Journal:  Eur Heart J       Date:  2011-02-02       Impact factor: 29.983

View more
  5 in total

1.  Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA5m chelators.

Authors:  Euy Sung Moon; Filipe Elvas; Gwendolyn Vliegen; Stef De Lombaerde; Christel Vangestel; Sven De Bruycker; An Bracke; Elisabeth Eppard; Lukas Greifenstein; Benedikt Klasen; Vasko Kramer; Steven Staelens; Ingrid De Meester; Pieter Van der Veken; Frank Rösch
Journal:  EJNMMI Radiopharm Chem       Date:  2020-07-29

2.  From Automated Synthesis to In Vivo Application in Multiple Types of Cancer-Clinical Results with [68Ga]Ga-DATA5m.SA.FAPi.

Authors:  Lukas Greifenstein; Carsten S Kramer; Euy Sung Moon; Frank Rösch; Andre Klega; Christian Landvogt; Corinna Müller; Richard P Baum
Journal:  Pharmaceuticals (Basel)       Date:  2022-08-14

3.  Overcoming stromal barriers to immuno-oncological responses via fibroblast activation protein-targeted therapy.

Authors:  W Nathaniel Brennen; Daniel L J Thorek; Wen Jiang; Timothy E Krueger; Lizamma Antony; Samuel R Denmeade; John T Isaacs
Journal:  Immunotherapy       Date:  2020-11-05       Impact factor: 4.196

4.  In Vitro Evaluation of the Squaramide-Conjugated Fibroblast Activation Protein Inhibitor-Based Agents AAZTA5.SA.FAPi and DOTA.SA.FAPi.

Authors:  Euy Sung Moon; Yentl Van Rymenant; Sandeep Battan; Joni De Loose; An Bracke; Pieter Van der Veken; Ingrid De Meester; Frank Rösch
Journal:  Molecules       Date:  2021-06-08       Impact factor: 4.411

Review 5.  Cancer-Associated Fibroblasts as Players in Cancer Development and Progression and Their Role in Targeted Radionuclide Imaging and Therapy.

Authors:  Sofia Koustoulidou; Mark W H Hoorens; Simone U Dalm; Shweta Mahajan; Reno Debets; Yann Seimbille; Marion de Jong
Journal:  Cancers (Basel)       Date:  2021-03-04       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.